Search

Your search keyword '"Rajender Reddy, K."' showing total 228 results

Search Constraints

Start Over You searched for: Author "Rajender Reddy, K." Remove constraint Author: "Rajender Reddy, K."
228 results on '"Rajender Reddy, K."'

Search Results

2. FRI-086 Untargeted serum metabolomic profiles remain stable over time in large multi-center cohort of >700 outpatients with cirrhosis

3. FRI-046 Alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort

5. Clinical Dilemmas in Viral Liver Disease

8. Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients

9. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)

10. 1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors

14. Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: Results from the PROP UP study

15. Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax

19. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

28. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.

29. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

30. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.

31. Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax.

35. Reply

36. Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) With and Without Type 2 Diabetes Mellitus (T2DM)

37. IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies

38. P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies

39. Albumin Use and Acute Kidney Injury in a Large Real-World Analysis of Cirrhotic Inpatients

42. Hepatitis B

44. Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin for 12 Weeks in Subjects with Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Galaxy Study

45. Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection

46. Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection.

47. Underreporting of Liver Transplant Waitlist Removals due to Death or Clinical Deterioration: Results at 4 Major Centers

50. P0889 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection

Catalog

Books, media, physical & digital resources